Korean J Intern Med.
2008 Mar;23(1):30-36. 10.3904/kjim.2008.23.1.30.
Epstein-Barr Virus-Positivity in Tumor has no Correlation with the Clinical Outcomes of Patients with Angioimmunoblastic T-cell Lymphoma
- Affiliations
-
- 1Division of Hematology Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Inchon, Korea.
- 2Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. dbs@gilhospital.com
- 3Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 4Division of Hematology-Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 5Department of Hematology-Oncology, Gyeongsang National University Hospital, Jinju, Korea.
- 6Department of Hematology-Oncology, Korea Cancer Center Hospital, Seoul, Korea.
- KMID: 1382659
- DOI: http://doi.org/10.3904/kjim.2008.23.1.30
Abstract
- BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear. This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival. METHODS: Seventy AILT cases were identified over a period of 8 years. Twenty seven cases were investigated for their EBV tumor status, and 10 BM samples of these patients were investigated for their EBV status with using in situ hybridization (ISH). EBV PCR was performed for the BM mononuclear cells in 8 cases. RESULTS: Among the 27 tumor specimens, ten (37%) were EBV-positive. Only CD20-negativity in tumor correlated with the EBV-positivity (p=0.035). In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis. Among the 10 patients who had additional BM slides available, there were 3 with BM involvement, and none showed EBV positive results on ISH. EBV PCR of the BM mononuclear cells revealed one-positive case among 8 patients. This patient was negative for both BM involvement and EBV ISH. The median overall survival of the 25 treated patients was 48.9 months (95% CI: 18.6~79.2 months). Neither overall survival nor progression-free survival was related with EBV-positivity of the tumor. CONCLUSIONS: EBV-positivity of tumor had no impact on the prognosis of AILT patients.
MeSH Terms
-
Adolescent
Adult
Aged
Bone Marrow/virology
DNA, Viral/isolation & purification
Female
Herpesvirus 4, Human/*isolation & purification
Humans
Immunoblastic Lymphadenopathy/mortality/*virology
In Situ Hybridization
Lymphoma, T-Cell/mortality/*virology
Male
Middle Aged
Polymerase Chain Reaction
Prognosis
Survival Analysis
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Epstein-Barr Virus-positive Diffuse, Large B-cell Lymphoma after Angioimmunoblastic T-cell Lymphoma
- Two Cases of the Angioimmunoblastic Lymphadenopathy Type of Peripheral T - cell Lymphoma : Different Clinical Courses According to Positivity to Epstein-Barr Virus
- A Case of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Occurring in Thyroid Gland
- A Case of Cutaneous Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma in an Angioimmunoblastic T-Cell Lymphoma
- A Case of Epstein-Barr Virus-associated Primary Gastric T-cell Lymphoma with Rapidly Progressive Endoscopic Features and Clinical Course
